ummary: In a series of 27 recipients of cadaver kidney grafts, 26 were at the time of writing alive, 3 to 25 months after transplantation, and 25 patients were alive with functioning first grafts. The one-year patient survival in 18 patients was 94% and the one-year graft survival was 89%. There was no beneficial correlation between tissue matching and the frequency of major early rejection episodes or graft function 12 or more months after transplantation. Antilymphocyte globulin administration was associated with a lower incidence of early rejection episodes, but this was not statistically significant. A combination of prophylactic graft irradiation and antilymphocyte globulin administration for at least the frst two weeks was associated with a significantly reduced frequency of major early rejection episodes and appreciably better graft function at 12 months. This effect could not be ascribed to better tissue matching.
Introduction
There is no complete certainty about the value of histocompatibility matching, the use of antilymphocyte globulin, or the use of prophylactic graft irradiation in human cadaver kidney transplantation. This report analyses the effects of these three variables against a background of standardized basic immunosuppressive therapy in a series of 27 cadaver kidney transplants performed in a two-year period.
Patients and Methods
Patients.-Previous experience with hyperacute rejection in three patients has been published (Myburgh et al., 1969) .
Twenty-eight patients received cadaver kidney transplants for the first time at the Johannesburg General Hospital in the two-year period ending February 1970. Hyperacute rejection occurred in one of these patients despite a negative lymphocytotoxicity reaction between recipient serum and donor lymphocytes. The remaining 27 (Calne et al., 1969; Marshall et al., 1968; Moore and Hume, 1969) . In the present series of 27 cadaver kidney recipients only one kidney has been lost from rejection 3 to 25 months after transplantation, and the only death occurred from pulmonary embolism five months after transplantation in a patient with normal graft function. The one-year patient survival in 18 patients is 94% and the one-year graft survival is 89%. Moore and Hume (1969) stated that the critical period for assessing cadaver kidney transplantation is probably two years as, in their experience, there was a substantial fall-off from 70% to 48 % between one and two years. In the present series all five patients transplanted 18 to 25 months ago have functioning first grafts, but mean serum creatinine levels for the entire group show a gradual rise with the passage of time (Fig. 2) . This probably reflects the effect of chronic humorally mediated rejection.
It is notoriously difficult to assess the effects of individual factors in the complex setting of human kidney transplantations. In the present series a standardized basic immunosuppressive regimen has facilitated the analysis of the effects of three variable factors-tissue matching, antilymphocyte globulin administration, and prophylactic graft irradiation.
There is now very strong evidence that compatibility with respect to the HL-A system significantly influences the outcome of kidneys transplanted from related living donors, particularly in sib-sib combinations (Singal et al., 1969) . Evidence for such an effect in grafts from cadaver donors has been much less convincing, but it does suggest an influence on both long-term (Patel et al., 1968; Batchelor and Joysey, 1969; van Rood, 1969 ) and short-term (Murray et al., 1967) suggested that prophylactic graft irradiation had a beneficial effect on the course of cadaveric renal transplantation. This was not confirmed in a subsequent report (Advisory Committee of the Human Kidney Transplant Registry, 1969). Individual centres using prophylactic graft irradiation, however, have reported excellent results in cadaveric kidney transplantation Moore and Hume, 1969) . In the present series patients receiving a combination of prophylactic graft irradiation and two weeks or more of antilymphocyte globulin fared better than patients receiving graft irradiation without antilymphocyte globulin or patients receiving these modalities of treatment in an erratic way. This effect was not associated with better tissue matching. It was statistically significant with respect to the occurrence of major early rejection episodes and appreciable, though not significant at the 5 % level, with respect to graft function at 12 months. The beneficial effects of avoiding major early rejection episodes on late graft function was also apparent for the entire series.
